Immunotherapy in Malignant Pleural Mesothelioma

Frontiers in Oncology
Cornedine J de GooijerPaul Baas

Abstract

The only registered systemic treatment for malignant pleural mesothelioma (MPM) is platinum based chemotherapy combined with pemetrexed, with or without bevacizumab. Immunotherapy did seem active in small phase II trials. In this review, we will highlight the most important immunotherapy-based research performed and put a focus on the future of MPM. PD-(L)1 inhibitors show response rates between 10 and 29% in phase II trials, with a wide range in progression free (PFS) and overall survival (OS). However, single agent pembrolizumab was not superior to chemotherapy (gemcitabine or vinorelbine) in the recent published PROMISE-Meso trial in pre-treated patients. In small studies with CTLA-4 inhibitors there is evidence for response in some patients, but it fails to show a better PFS and OS compared to best supportive care in a randomized study. A combination of PD-(L)1 inhibitor with CTLA-4 inhibitor seem to have a similar response as PD-(L)1 monotherapy. The first results of combining durvalumab (PD-L1 blocking) with cisplatin-pemetrexed in the first line are promising. Another immune treatment is Dendritic Cell (DC) immunotherapy, which is recently tested in mesothelioma, shows remarkable anti-tumor activity in three clinical stu...Continue Reading

References

Apr 1, 2008·The Journal of Thoracic and Cardiovascular Surgery·Masaki AnrakuMarc de Perrot
Feb 20, 2010·American Journal of Respiratory and Critical Care Medicine·Joost P HegmansJoachim G Aerts
Jun 23, 2010·Cancer Immunology, Immunotherapy : CII·Noriyuki YamadaMasaharu Nishimura
Nov 4, 2011·The Journal of Immunology : Official Journal of the American Association of Immunologists·Carlos AlfaroIgnacio Melero
Jun 14, 2014·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Aaron Scott MansfieldEugene D Kwon
Sep 23, 2014·Cancer Immunology, Immunotherapy : CII·Luana CalabròMichele Maio
Dec 15, 2015·American Journal of Respiratory and Critical Care Medicine·Robin CornelissenJoachim G J V Aerts
May 22, 2016·Cancer Immunology, Immunotherapy : CII·Silvio RoncellaMaria Pia Pistillo
Oct 25, 2016·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Swati KhannaRaffit Hassan
Nov 12, 2016·Proceedings of the National Academy of Sciences of the United States of America·Yoshie YoshikawaMichele Carbone
Sep 26, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·N I ChernyE G E de Vries
Dec 14, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Joachim G J V AertsHenk C Hoogsteden
Dec 21, 2017·The New England Journal of Medicine·Mark YarchoanElizabeth M Jaffee
Jun 17, 2018·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Josine Quispel-JanssenPaul Baas
Jun 25, 2018·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Anne S TsaoRitu R Gill
Aug 25, 2018·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Yannis MetaxasThomas John
Oct 29, 2018·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Cornedine J de Gooijer, Paul Baas
Feb 21, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dean A FennellJoachim G J V Aerts
Jun 6, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Morihito OkadaYuichiro Ohe

❮ Previous
Next ❯

Citations

Apr 12, 2020·Cancers·Fabio NicoliniMassimiliano Mazza
Jun 21, 2020·International Journal of Molecular Sciences·Vasiliki Panou, Oluf Dimitri Røe
Nov 27, 2020·Therapeutic Advances in Medical Oncology·Haitang YangRen-Wang Peng
Oct 14, 2020·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Daniel OrbachMyriam Ben Arush
Apr 30, 2021·Science Translational Medicine·Axel Hyrenius-WittstenKole T Roybal
May 19, 2021·Cancer Immunology, Immunotherapy : CII·Beatrice DozinMarina Fabbi
Jul 3, 2021·Cancers·Anne-Laure DésageMarios E Froudarakis
Jul 29, 2021·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Roger Y KimAnil Vachani
Jan 2, 2021·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Anne-Marie BairdOrla Sheils

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT02899299
NCT02784171
NCT03762018

Software Mentioned

NIBIT
irRECIST
mRECIST
MESO
iRECIST
DETERMINE
ETOP PROMISE

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.